Catherine Bresson
Director, Operational Team, WIN Consortium
Executive committee
Razelle Kurzrock
Chief, Division of Hematology & Oncology, Sr. Deputy Center Director for Clinical Science, University of California San Diego Moores Cancer Center (USA)
Vladimir Lazar
Chief Scientific and Operating Officer, WIN Consortium
Brian Leyland-Jones
Vice President of Molecular and Experimental Medicine, Avera Cancer Institute (USA)
John Mendelsohn
Director, Khalifa Institute for Personalized Cancer Medicine and Past-President, the University of Texas MD Anderson Cancer Center (USA)
Amir Onn
Head, Institute of Pulmonary Oncology, Sheba Medical Center (Israel)
Richard L. Schilsky
Senior Vice President and Chief Medical Officer, American Society of Clinical Oncology (ASCO)
Josep Tabernero
Director and Clinical Research Director, Vall d'Hebron Institute of Oncology, VHIO (Spain); ESMO President (2018 – 2019); Chair, WIN Scientific Advisory Board
Apostolia-Maria Tsimberidou
Tenured Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Operational team
Catherine Bresson
Director, Operational Team, WIN Consortium
Layla El-Gharras
Assistant, Operational Team, WIN Consortium
Vladimir Lazar
Chief Scientific and Operating Officer, WIN Consortium
Eitan Rubin
Senior Lecturer, Ben-Gurion University of the Negev (Israel); Head, WIN IT Platform
Fanny Wunder
Project Manager, WIN Consortium
Scientific Advisory Board
Sung-Min Ahn
Associate Professor, Division of Oncology, Department of Internal Medicine, Gachon University Gil Medical Center (South Korea)
Phillip Febbo
Chief Medical Officer, Illumina (USA)
Robert Grossman
Faculty, Senior Fellow, Searle Chemistry Laboratory, University of Chicago (USA)
Stanley R. Hamilton
Head of Pathology & Laboratory Medicine Labs, The University of Texas, MD Anderson Cancer Center (USA)
Leroy Hood
President and Co-Founder, Institute for Systems Biology (USA)
Pasi A. Jänne
Scientific Director, Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute (USA)
Yves Luisser
Associate Vice President for Health Sciences, The University of Arizona Cancer Center (USA)
John Quackenbush
Professor, Biostatistics & Computational Biology, Dana-Farber Cancer Institute (USA)
Gideon Rechavi
Head, Sheba Cancer Research Center, Chaim Sheba Medical Center (Israel)
Gary L. Rosner
Director, Division of Biostatistics and Bioinformatics, Department of Oncology, John Hopkins Medicine (USA)
Lillian Siu
Senior Staff Physician, Division of Medical Oncology and Hematology, Princess Margaret Hospital (Canada)
Alan Spatz
Director, Department of Pathology & Professor of Pathology & Oncology, Jewish General Hospital & McGill University (Canada)
Josep Tabernero
Director and Clinical Research Director, Vall d'Hebron Institute of Oncology, VHIO (Spain); ESMO President (2018 – 2019); Chair, WIN Scientific Advisory Board
Yosef Yarden
Professor, Weizmann Institute of Science (Israel)
Directorate
Gerald Batist
Professor & Chair, Department of Oncology, McGill University and Director, Segal Cancer Center (Canada)
Pierre Fumoleau
General Manager, Institut Curie Hospital Group, Paris (France)
Nicolas Girard
Head of Department, Medical Oncology, Institut Curie (France)
Razelle Kurzrock
Chief, Division of Hematology & Oncology, Sr. Deputy Center Director for Clinical Science, University of California San Diego Moores Cancer Center (USA)
Ulrik Lassen
Professor, Head of Phase 1 Unit, Rigshospitalet (Denmark)
Brian Leyland-Jones
Vice President of Molecular and Experimental Medicine, Avera Cancer Institute (USA)
Frank Makosiej
Executive Director, Operational Strategy and Planning, Clinical Development Services, Covance, Inc.(USA)
Jean-François Martini
Senior Director, Translational Oncology, Global Product Development-Oncology, Pfizer, Inc. (USA)
Amir Onn
Head, Institute of Pulmonary Oncology, Sheba Medical Center (Israel)
Alejandro Piris
Scientific Research Manager, Vall d'Hebron Institute of Oncology, VHIO (Spain)
Angel Porgador
Associate Professor, Ben-Gurion University of the Negev (Israel)
C.S. Pramesh
Chief, Thoracic Surgery, Division of Surgical Oncology, ACTREC - Tata Memorial Center (India)
Jacques Raynaud
President, Fondation ARC (France)
Eitan Rubin
Senior Lecturer, Ben-Gurion University of the Negev (Israel); Head, WIN IT Platform
Richard L. Schilsky
Senior Vice President and Chief Medical Officer, American Society of Clinical Oncology (ASCO)
Benjamin M. Solomon
Asst Professor of Medicine, Avera Cancer Institute (USA)
Alan Spatz
Director, Department of Pathology & Professor of Pathology & Oncology, Jewish General Hospital & McGill University (Canada)
Josep Tabernero
Director and Clinical Research Director, Vall d'Hebron Institute of Oncology, VHIO (Spain); ESMO President (2018 – 2019); Chair, WIN Scientific Advisory Board
Apostolia-Maria Tsimberidou
Tenured Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Ding-Wei Ye
Vice President International Affairs & Professor, Chairman of Department of Urology, Fudan University Shanghai Cancer Center (China)
Chang Sik Yu
President, Asan Medical Center Cancer Institute (South Korea)
Luis Eduardo Rosa Zucca
Medical Oncologist, Department of Clinical Oncology - Neoplasms Sector Genitourinary, Fundaçao Pio XII - Hospital de Câncer de Barretos (Brazil)
General Assembly
Taher Abu Hejleh
King Hussein Cancer Center (Jordan)
Mohammad Afshar
CEO, Ariana Pharmaceuticals (France)
Diana Aguirre
Senior Medical Director, Covance, Inc. (USA)
Hee Kyung Ahn
Assistant Professor, Division of Hematology and Oncology, Gachon University Gil Medical Center (South Korea)
Amal Al Omari
Director, Office of Scientific Affairs and Research, King Hussein Cancer Center (Jordan)
Gerald Batist
Professor & Chair, Department of Oncology, McGill University and Director, Segal Cancer Center (Canada)
Guy Berchem
Medical Oncologist,Centre Hospitalier de Luxembourg (Luxembourg)
Raanan Berger
Director, Institute of Oncology, Sheba Medical Center (Israel)
Jean-Yves Blay
Professor of Medicine, Université Claude Bernard; Scientific Director, Canceropole Lyon Rhône Alpes, Centre Léon Bérard (France)
Rares Buiga
The Oncology Institute Ion Chiricuta (IOCN) (Romania)
David Cantú
Clinical Research, Instituto Nacional de Cancerologia (INCan)
Andrés Cervantes
Head of Section in Medical Oncology, INCLIVA (Spain)
Francesco De Lorenzo
President, European Cancer Patient Coalition - ECPC (Belgium)
Franck Dufour
Scientific Director, Fondation ARC (France)
Matt Ellefson
Founder & CEO of SURVIVEiT®, (USA)
Trent Haywood
Chief Medical Officer, The Blue Cross and Blue Shield Association (USA)
Luis A. Herrera
Senior Researcher "C" of TC Definitivo of the Institute of Biomedical Research, Instituto Nacional de Cancerologia (INCan)
William Hwang
Medical Director, National Cancer Centre Singapore (Singapore)
Susan Galbraith
Senior Vice-President IMED Oncology, AstraZeneca, Cambridge, UK
Jean Claude Gerard
VP Commercial Operations Europe, HTG Molecular (France)
Nicolas Girard
Head of Department, Medical Oncology, Institut Curie (France)
Sadakatsu Ikeda
Junior Associate Professor, Deputy Director, Tokyo Medical and Dental University Cancer Center (Japan)
Alexandru Irimie
The University of Medicine and Pharmacy Iuliu Haţieganu (Romania)
Timothy Johnson
President and Chief Executive Officer, HTG Molecular (USA)
Masashi Kanai
Associate Professor, Department of Clinical Oncology, Pharmacogenomics and Palliative Medicine, Graduate School of Medicine, Kyoto University Hospital (Japan)
Tae Won Kim
Director, Clinical Research Center & Center for Personalized Cancer Medicine (Korea)
Gautam Kollu
Head of Market Development, Illumina (USA)
Razelle Kurzrock
Chief, Division of Hematology & Oncology, Sr. Deputy Center Director for Clinical Science, University of California San Diego Moores Cancer Center (USA)
Tanel Laisaar
Head of Thoracic Surgery, Department of Pulmonology and Thoracic Surgery, Lung Clinic, Tartu University Hospital (Estonia)
Catherine Larue
CEO, Luxembourg Institute of Health (Luxembourg)
Ulrik Lassen
Professor, Head of Phase 1 Unit, Rigshospitalet (Denmark)
Brian Leyland-Jones
Vice President of Molecular and Experimental Medicine, Avera Cancer Institute (USA)
Scott M. Lippman
Director, University of California San Diego Moores Cancer Center (USA)
Frank Makosiej
Executive Director, Operational Strategy and Planning, Clinical Development Services, Covance, Inc.(USA)
Isabelle Manneh-Vangramberen
Head of Health and Research Programmes, European Cancer Patient Coalition - ECPC (Belgium)
Jean-François Martini
Senior Director, Translational Oncology, Global Product Development-Oncology, Pfizer, Inc. (USA)
Giorgio Massimini
Vice President, Head Medical Officer, New Businesses;Biopharma, Global Research & Development, Merck Group KGaA (Germany)
John Mendelsohn
Director, Khalifa Institute for Personalized Cancer Medicine and Past-President, the University of Texas MD Anderson Cancer Center (USA)
Ni Ming
Director, Office of Shanghai Anti-cancer and Office of International Affairs, Fudan University Shanghai Cancer Center (China)
Satoshi Miyake
Director, Tokyo Medical and Dental University Cancer Center (Japan)
Manabu Muto
Professor, Department of Therapeutic Oncology, Graduate School of Medicine, Head, Department of Clinical Oncology, Kyoto University Hospital (Japan)
Ioana Berindean Neagoe
Scientific Director, The University of Medicine and Pharmacy Iuliu Hatieganu (Romania)
Hovav Nechushtan
Associate Professor, Oncology Department, Hadassah Hebrew University Medical School (Israel)
Benjamin Neel
Director, Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center (USA)
Finn Cilius Nielsen
Professor and Head, Genomic Medicine, Rigshospitalet (Denmark)
Johannes Nippgen
R&D Program Lead & Clinical Lead - Erbitux, Merck Group KGaA (China)
Amir Onn
Head, Institute of Pulmonary Oncology, Sheba Medical Center (Israel)
Iman Osman
Associate Director, Cancer Institute, Director, Interdisciplinary Melanoma Program, New York University Langone Medical Center (USA)
Peeter Padrik
Director of Cancer Centre, Tartu University Hospital (Estonia)
Prithwish Pal
Manager, Market Development, Oncology, Illumina (USA)
Tamar Peretz-Yablonski
Head Department of Oncology, Hadassah Medical Center (Israel)
Thierry Philip
Chairman of the Board of Directors, Institut Curie (France)
Alejandro Piris
Scientific Research Manager, Vall d'Hebron Institute of Oncology, VHIO (Spain)
Angel Porgador
Associate Professor, Ben-Gurion University of the Negev (Israel)
C.S. Pramesh
Chief, Thoracic Surgery, Division of Surgical Oncology, ACTREC - Tata Memorial Center (India)
Eric Raymond
Head of Medical Oncology, Groupe Hospitalier Paris Saint-Joseph (France)
Jacques Raynaud
President, Fondation ARC (France)
Rui Manuel Reis
Coordinator, Molecular Oncology Research Center, Fundaçao Pio XII - Hospital de Câncer de Barretos (Brazil)
Gloria Ribas
Researcher, INCLIVA (Spain)
Eitan Rubin
Senior Lecturer, Ben-Gurion University of the Negev (Israel); Head, WIN IT Platform
Pierre Saintigny
Laboratory of Translational Research, Department of Translational Research and Innovation, Centre Léon Bérard (France)
Marc Schlesser
Pneumologist, Pneumology Department, Centre Hospitalier de Luxembourg (Luxembourg)
Marina Sekacheva
Head of Center for Personalized Cancer Therapy, Sechenov First Moscow State Medical University (Russia)
Manju Sengar
Medical Oncologist and Officer in charge, Clinical Research Secretariat, ACTREC - Tata Memorial Center (India)
Benjamin M. Solomon
Asst Professor of Medicine, Avera Cancer Institute (USA)
Jean-Charles Soria
Senior Vice President, Head of Oncology Innovative Medicines, MedImmune, USA
Alan Spatz
Director, Department of Pathology & Professor of Pathology & Oncology, Jewish General Hospital & McGill University (Canada)
Andrey A. Svistunov
First Vice Rector for Innovation and International Affairs, I.M Sechenov First Moscow State Medical University (Russia)
Sun-Jin Sym
Gachon University Gil Medical Center (South Korea)
Josep Tabernero
Director and Clinical Research Director, Vall d'Hebron Institute of Oncology, VHIO (Spain); ESMO President (2018 – 2019); Chair, WIN Scientific Advisory Board
Tira Tan
Consultant, Division of Medical Oncology, National Cancer Centre Singapore (NCCS)Singapore
George Wilding
Vice Provost, Clinical and Interdisciplinary Research, The University of Texas, MD Anderson Cancer Center (USA)
Casey Williams
Director of Molecular and Experimental Medicine, Avera Cancer Institute (USA)
Ding-Wei Ye
Vice President International Affairs & Professor, Chairman of Department of Urology, Fudan University Shanghai Cancer Center (China)
Chang Sik Yu
President, Asan Medical Center Cancer Institute (South Korea)
Luis Eduardo Rosa Zucca
Medical Oncologist, Department of Clinical Oncology - Neoplasms Sector Genitourinary, Fundaçao Pio XII - Hospital de Câncer de Barretos (Brazil)